This content is from: Premium
Kodiak Reminds Perceptive Advisors of the Risks of IPOs
The hedge fund headed by Joseph Edelman more than doubled its stake in the biopharmaceutical company.
This was no doubt a bittersweet deal for Joseph Edelman’s Perceptive Advisors.When Kodiak Sciences was gearing up to go public earlier this month, the developmental-stage biopharmaceutical company planned to offer 9 million shares for between $13 and $15 per share.But when it finally began trading on October 4, the IPO
To continue reading, subscribe now to Premium Journalism. Already a subscriber? Login.